Cencora, Inc.
Get $10 bonus on your first $100 deposit for COR
Get $10 bonus on your first $100 deposit for COR
Cencora, Inc. (COR) Stock Competitors & Peer Comparison
See (COR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| COR | $320.89 | -0.02% | 62.4B | 38.62 | $8.31 | +0.72% |
| MCK | $856.62 | -0.02% | 105.7B | 24.71 | $34.66 | +0.37% |
| CAH | $212.77 | +0.07% | 50.1B | 30.57 | $6.96 | +0.96% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $73.85 | -1.35% | 8.7B | 22.58 | $3.27 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +1.66% |
| PBH | $55.62 | +0.89% | 2.7B | 14.69 | $3.79 | N/A |
| GRDN | $39.26 | +2.13% | 2.5B | 50.29 | $0.78 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
| ACH | $2.54 | -5.75% | 195.3M | -1.91 | -$1.34 | N/A |
Stock Comparison
COR vs MCK Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, MCK has a market cap of 105.7B. Regarding current trading prices, COR is priced at $320.89, while MCK trades at $856.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas MCK's P/E ratio is 24.71. In terms of profitability, COR's ROE is +1.01%, compared to MCK's ROE of -2.45%. Regarding short-term risk, COR is less volatile compared to MCK. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check MCK's competition here
COR vs CAH Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, CAH has a market cap of 50.1B. Regarding current trading prices, COR is priced at $320.89, while CAH trades at $212.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas CAH's P/E ratio is 30.57. In terms of profitability, COR's ROE is +1.01%, compared to CAH's ROE of -0.59%. Regarding short-term risk, COR is less volatile compared to CAH. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check CAH's competition here
COR vs ABC Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, COR is priced at $320.89, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas ABC's P/E ratio is 21.92. In terms of profitability, COR's ROE is +1.01%, compared to ABC's ROE of +1.01%. Regarding short-term risk, COR is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check ABC's competition here
COR vs HSIC Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, HSIC has a market cap of 8.7B. Regarding current trading prices, COR is priced at $320.89, while HSIC trades at $73.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas HSIC's P/E ratio is 22.58. In terms of profitability, COR's ROE is +1.01%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, COR is less volatile compared to HSIC. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check HSIC's competition here
COR vs PDCO Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, COR is priced at $320.89, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas PDCO's P/E ratio is 20.48. In terms of profitability, COR's ROE is +1.01%, compared to PDCO's ROE of +0.06%. Regarding short-term risk, COR is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check PDCO's competition here
COR vs PBH Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, PBH has a market cap of 2.7B. Regarding current trading prices, COR is priced at $320.89, while PBH trades at $55.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas PBH's P/E ratio is 14.69. In terms of profitability, COR's ROE is +1.01%, compared to PBH's ROE of +0.10%. Regarding short-term risk, COR is less volatile compared to PBH. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check PBH's competition here
COR vs GRDN Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, GRDN has a market cap of 2.5B. Regarding current trading prices, COR is priced at $320.89, while GRDN trades at $39.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas GRDN's P/E ratio is 50.29. In terms of profitability, COR's ROE is +1.01%, compared to GRDN's ROE of +0.28%. Regarding short-term risk, COR is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check GRDN's competition here
COR vs OMI Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, COR is priced at $320.89, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas OMI's P/E ratio is -0.47. In terms of profitability, COR's ROE is +1.01%, compared to OMI's ROE of +7.33%. Regarding short-term risk, COR is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check OMI's competition here
COR vs ACH Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, ACH has a market cap of 195.3M. Regarding current trading prices, COR is priced at $320.89, while ACH trades at $2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas ACH's P/E ratio is -1.91. In terms of profitability, COR's ROE is +1.01%, compared to ACH's ROE of +7.33%. Regarding short-term risk, COR is less volatile compared to ACH. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check ACH's competition here
COR vs GEG Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, GEG has a market cap of 56.1M. Regarding current trading prices, COR is priced at $320.89, while GEG trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas GEG's P/E ratio is -4.14. In terms of profitability, COR's ROE is +1.01%, compared to GEG's ROE of -0.21%. Regarding short-term risk, COR is less volatile compared to GEG. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check GEG's competition here
COR vs HX Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, COR is priced at $320.89, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas HX's P/E ratio is -1.84. In terms of profitability, COR's ROE is +1.01%, compared to HX's ROE of -1.07%. Regarding short-term risk, COR is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check HX's competition here
COR vs WGRX Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, WGRX has a market cap of 9.1M. Regarding current trading prices, COR is priced at $320.89, while WGRX trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas WGRX's P/E ratio is -0.09. In terms of profitability, COR's ROE is +1.01%, compared to WGRX's ROE of +1417.60%. Regarding short-term risk, COR is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check WGRX's competition here
COR vs SNYR Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, SNYR has a market cap of 6M. Regarding current trading prices, COR is priced at $320.89, while SNYR trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas SNYR's P/E ratio is -0.53. In terms of profitability, COR's ROE is +1.01%, compared to SNYR's ROE of +0.83%. Regarding short-term risk, COR is less volatile compared to SNYR. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check SNYR's competition here
COR vs ZYXI Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, COR is priced at $320.89, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, COR's ROE is +1.01%, compared to ZYXI's ROE of -18.07%. Regarding short-term risk, COR is more volatile compared to ZYXI. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check ZYXI's competition here
COR vs MEHA Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, MEHA has a market cap of 1.4M. Regarding current trading prices, COR is priced at $320.89, while MEHA trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas MEHA's P/E ratio is 19.94. In terms of profitability, COR's ROE is +1.01%, compared to MEHA's ROE of +1.19%. Regarding short-term risk, COR is less volatile compared to MEHA. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check MEHA's competition here
COR vs RDGT Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, RDGT has a market cap of 155.7K. Regarding current trading prices, COR is priced at $320.89, while RDGT trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas RDGT's P/E ratio is -0.07. In terms of profitability, COR's ROE is +1.01%, compared to RDGT's ROE of +0.42%. Regarding short-term risk, COR is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check RDGT's competition here
COR vs CVET Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 62.4B. In comparison, CVET has a market cap of 0. Regarding current trading prices, COR is priced at $320.89, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 38.62, whereas CVET's P/E ratio is -69.97. In terms of profitability, COR's ROE is +1.01%, compared to CVET's ROE of -0.06%. Regarding short-term risk, COR is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check CVET's competition here